NO308772B1 - Sublingual eller buckal farmasoytisk blanding inneholdende trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol, samt anvendelse av forbindelsen for fremstilling av farmasoytisk blanding - Google Patents

Sublingual eller buckal farmasoytisk blanding inneholdende trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol, samt anvendelse av forbindelsen for fremstilling av farmasoytisk blanding

Info

Publication number
NO308772B1
NO308772B1 NO19963639A NO963639A NO308772B1 NO 308772 B1 NO308772 B1 NO 308772B1 NO 19963639 A NO19963639 A NO 19963639A NO 963639 A NO963639 A NO 963639A NO 308772 B1 NO308772 B1 NO 308772B1
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
sublingual
buccal
oxepino
dibenz
Prior art date
Application number
NO19963639A
Other languages
English (en)
Norwegian (no)
Other versions
NO963639L (no
NO963639D0 (no
Inventor
Leonardus Petrus Carla Delbressine
Johannes Hubertus Wieringa
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO308772(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO963639D0 publication Critical patent/NO963639D0/no
Publication of NO963639L publication Critical patent/NO963639L/no
Publication of NO308772B1 publication Critical patent/NO308772B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19963639A 1994-03-02 1996-08-30 Sublingual eller buckal farmasoytisk blanding inneholdende trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol, samt anvendelse av forbindelsen for fremstilling av farmasoytisk blanding NO308772B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94200521 1994-03-02
PCT/EP1995/000765 WO1995023600A1 (en) 1994-03-02 1995-03-01 Sublingual or buccal pharmaceutical composition

Publications (3)

Publication Number Publication Date
NO963639D0 NO963639D0 (no) 1996-08-30
NO963639L NO963639L (no) 1996-10-30
NO308772B1 true NO308772B1 (no) 2000-10-30

Family

ID=8216678

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19963639A NO308772B1 (no) 1994-03-02 1996-08-30 Sublingual eller buckal farmasoytisk blanding inneholdende trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol, samt anvendelse av forbindelsen for fremstilling av farmasoytisk blanding
NO2010024C NO2010024I2 (no) 1994-03-02 2010-12-13 Trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol eller et salt derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2010024C NO2010024I2 (no) 1994-03-02 2010-12-13 Trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol eller et salt derav

Country Status (23)

Country Link
US (1) US5763476A (cs)
EP (1) EP0746317B1 (cs)
JP (2) JP4099224B2 (cs)
KR (1) KR100330942B1 (cs)
CN (1) CN1079670C (cs)
AT (1) ATE167057T1 (cs)
AU (1) AU692530B2 (cs)
BR (2) BR9506924A (cs)
CA (1) CA2182981C (cs)
CZ (1) CZ284633B6 (cs)
DE (2) DE69502939T2 (cs)
DK (1) DK0746317T3 (cs)
ES (1) ES2118584T3 (cs)
FI (1) FI117923B (cs)
FR (1) FR10C0056I2 (cs)
HK (1) HK1008417A1 (cs)
HU (1) HU225051B1 (cs)
LU (1) LU91751I2 (cs)
NO (2) NO308772B1 (cs)
NZ (1) NZ282394A (cs)
PL (1) PL180465B1 (cs)
RU (1) RU2139051C1 (cs)
WO (1) WO1995023600A1 (cs)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2418499A (en) * 1997-12-19 1999-07-12 Akzo Nobel N.V. Org-5222 in the treatment of depression
CN100556762C (zh) * 2002-02-13 2009-11-04 迈克尔K·韦伯尔 药物剂型及其制造方法
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
BRPI0410271A (pt) * 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight
WO2005030273A2 (en) * 2003-09-22 2005-04-07 Baxter International Inc. High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
GB0416861D0 (en) * 2004-07-29 2004-09-01 Quadrant Drug Delivery Ltd Composition
EP1802301A1 (en) * 2004-10-15 2007-07-04 Pfizer Inc. Treatment of bipolar disorders and associated symptoms
US7872147B2 (en) 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
SI1710241T1 (sl) 2005-04-07 2010-02-26 Organon Nv Intermediatne spojine za pripravo trans-5-kloro-2-metil-2,3,3a, 12b-tetrahidro-1H-dibenz(2,3:6,7)oksepino(4,5-C)pirola
EP1917267B1 (en) * 2005-04-07 2008-12-24 N.V. Organon Crystal form of asenapine maleate
US7741358B2 (en) * 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
US7750167B2 (en) 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
US7875729B2 (en) 2007-01-05 2011-01-25 Synthon Bv Process for making asenapine
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
WO2010127674A1 (en) * 2009-05-06 2010-11-11 Sunin K/S Transdermal compositions of asenapine for the treatment of psychiatric disorders
EP2453870A2 (en) 2009-06-24 2012-05-23 MSD Oss B.V. Injectable formulations containing asenapine and method of treatment using same
AR077429A1 (es) 2009-07-29 2011-08-24 Organon Nv Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos
CA2802990A1 (en) 2010-06-18 2011-12-22 Dr. Reddy's Laboratories Ltd. Asenapine maleate
US8653280B2 (en) 2010-07-29 2014-02-18 Laboratories Lesvi, S.L. Process for the preparation of asenapine
WO2012038975A2 (en) * 2010-09-22 2012-03-29 Msn Laboratories Limited Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
EP2640391B1 (en) 2010-11-15 2015-11-11 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012066565A2 (en) 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
US9533994B2 (en) 2011-05-18 2017-01-03 Laboratorios Lesvi S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
JP6014656B2 (ja) * 2011-05-18 2016-10-25 ラビラトリオス レスビ エス エレ 化合物の多形体
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
CN102657635B (zh) * 2012-05-04 2013-08-07 上海现代药物制剂工程研究中心有限公司 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9597291B2 (en) 2012-12-11 2017-03-21 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
CA3053189A1 (en) 2012-12-20 2014-06-26 Kashiv Biosciences, Llc Orally disintegrating tablet formulation for enhanced bioavailability
CN103893139B (zh) * 2012-12-28 2018-06-08 石药集团中奇制药技术（石家庄）有限公司 一种阿塞那平组合物及其制备方法
CN103120688A (zh) * 2013-01-11 2013-05-29 盛世泰科生物医药技术(苏州)有限公司 一种闪释制剂的药物组合
US9545376B2 (en) 2013-01-23 2017-01-17 Arx, Llc Production of unit dose constructs
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
IN2013MU02206A (cs) * 2013-06-28 2015-06-12 Alembic Pharmaceuticals Ltd
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
WO2015125152A2 (en) * 2014-02-18 2015-08-27 Hetero Research Foundation Pharmaceutical compositions of asenapine
CA2944512C (en) 2014-04-04 2018-04-24 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines for treatment of central nervous system disorders
TR201509009A1 (en) * 2014-12-11 2017-02-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi THIN FILM STRIP OF ASENAPINE
US11154510B2 (en) 2015-06-11 2021-10-26 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
WO2017165843A1 (en) 2016-03-25 2017-09-28 Intra-Cellular Therapies, Inc. Organic compounds
US10085971B2 (en) 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA3047451A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
JP7149287B2 (ja) 2016-12-20 2022-10-06 エルテーエス ローマン テラピー－ジステーメ アーゲー アセナピンおよびポリシロキサンまたはポリイソブチレンを含有する経皮治療システム
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
JP7132939B2 (ja) 2017-03-24 2022-09-07 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規組成物および方法
CA3067938A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
US12364694B2 (en) 2018-03-23 2025-07-22 Intra-Cellular Therapies, Inc. Organic compounds
NZ772066A (en) 2018-06-19 2025-05-30 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
ES3010131T3 (en) 2018-06-20 2025-04-01 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
WO2020047407A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
CN118873536A (zh) 2018-08-31 2024-11-01 细胞内治疗公司 新方法
JP7673040B2 (ja) 2019-07-07 2025-05-08 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
FR2480283A1 (fr) * 1980-04-10 1981-10-16 Science Union & Cie Nouveaux derives tricycliques, leurs procedes de preparation et leur utilisation comme medicament
JPS5967218A (ja) * 1982-10-07 1984-04-16 Grelan Pharmaceut Co Ltd 軟質な口腔製剤
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
CA2027243A1 (en) * 1989-10-17 1991-04-18 Everett H. Ellinwood, Jr. Intraoral formulated trifluorobenzodiazepines and the use thereof
DE69232374T2 (de) * 1991-04-08 2002-08-29 Koken Co. Ltd., Tokyo Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält
EP0569096A1 (en) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
CA2095499A1 (en) * 1992-05-08 1993-11-09 Petrus J. M. Van Den Oetelaar Depot preparation

Also Published As

Publication number Publication date
CZ284633B6 (cs) 1999-01-13
DK0746317T3 (da) 1999-03-22
PL316080A1 (en) 1996-12-23
FI963398A0 (fi) 1996-08-30
FR10C0056I1 (cs) 2011-01-28
AU692530B2 (en) 1998-06-11
WO1995023600A1 (en) 1995-09-08
DE122010000050I1 (de) 2011-05-05
HU9602383D0 (en) 1996-10-28
CN1143320A (zh) 1997-02-19
RU2139051C1 (ru) 1999-10-10
BR1100625A (pt) 1999-12-28
JP4616810B2 (ja) 2011-01-19
NZ282394A (en) 1997-12-19
DE69502939D1 (de) 1998-07-16
FI117923B (fi) 2007-04-30
NO963639L (no) 1996-10-30
JPH09509674A (ja) 1997-09-30
PL180465B1 (pl) 2001-02-28
CZ254196A3 (en) 1997-10-15
AU1947895A (en) 1995-09-18
NO2010024I1 (no) 2011-01-03
CA2182981A1 (en) 1995-09-08
CN1079670C (zh) 2002-02-27
FI963398L (fi) 1996-08-30
JP4099224B2 (ja) 2008-06-11
KR100330942B1 (ko) 2002-11-16
DE122010000050I2 (de) 2011-07-21
HK1008417A1 (en) 1999-05-07
CA2182981C (en) 2006-10-17
ES2118584T3 (es) 1998-09-16
FR10C0056I2 (cs) 2011-11-25
ATE167057T1 (de) 1998-06-15
NO2010024I2 (no) 2012-04-10
BR9506924A (pt) 1997-09-30
US5763476A (en) 1998-06-09
NO963639D0 (no) 1996-08-30
MX9603713A (es) 1997-12-31
LU91751I2 (fr) 2011-01-04
EP0746317B1 (en) 1998-06-10
HUT76319A (en) 1997-08-28
DE69502939T2 (de) 1998-10-22
JP2006342178A (ja) 2006-12-21
HU225051B1 (en) 2006-05-29
EP0746317A1 (en) 1996-12-11

Similar Documents

Publication Publication Date Title
NO308772B1 (no) Sublingual eller buckal farmasoytisk blanding inneholdende trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol, samt anvendelse av forbindelsen for fremstilling av farmasoytisk blanding
CA2293823A1 (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
CA2272705A1 (en) Fused bicyclic pyrimidine derivatives
UA70298A (uk) Похідні с-4"-заміщених макролідів, спосіб їх одержання, проміжні сполуки, фармацевтична композиція та спосіб лікування бактеріальної інфекції або протозойної інфекції
CA2316921A1 (en) Aryl fused azapolycyclic compounds
RU96120090A (ru) Сублингвальная или трансбуккальная фармацевтическая композиция
CA2115663A1 (en) Storage-Stable Polysiloxane Composition Which Gives Permanently Water-Wettable Vulcanizates
AU3563695A (en) Novel piperidine derivatives with paf antagonist activity
CA2314154A1 (en) Azepine or larger medium ring derivatives and their use as pharmaceuticals
AU1579688A (en) Bisphenylalkylpiperazine derivatives, a method of their preparation and a pharmaceutical preparation
TW252979B (cs)
AU1998995A (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
NO308852B1 (no) Indol-2,3-dion-3-oksim-derivater, farmasøytisk blanding og anvendelse av forbindelsen
AU6519596A (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
AU5608790A (en) New pyrrolidone derivatives, the process for their preparation and the pharmaceutical compositions containing them
AU2287197A (en) Heterocyclic compounds and their preparation and use
IL115004A (en) Pharmaceutical compositions containing substituted 6-amino-4H-pyrans certain novel such compounds and their preparation
EP0276805A3 (en) Substituted 3-phenyl-7h-thiazoloû3,2-b¨û1,2,4¨triazin-7-ones, processes for their preparation, medicaments containing them and their use as well as some of the intermediates obtained during the preparation of said compounds
WO2000037465A3 (en) Novel derivatives of swainsonine, processes for their preparation, and their use as therapeutic agents
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: SYCREST-ASENAPIN; NAT. REG. NO/DATE: EU/1/10/640/001/NO- 20101115; FIRST REG. NO/DATE: EU/1/10/640/001-006 20100901

Spc suppl protection certif: 2010024

Filing date: 20101213

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: SYCREST-ASENAPIN; NAT. REG. NO/DATE: EU/1/10/640/001/NO- 20101115; FIRST REG. NO/DATE: EU/1/10/640/001-006 20100901

Spc suppl protection certif: 2010024

Filing date: 20101213

Extension date: 20200301

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP & DOHME BV, NL

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2010024

Effective date: 20200302